Abstract: High-speed ADCs are critical in applications spanning from wideband wireless communication to ultra-high-speed wireline and optical links, but achieving rapid operation poses unique design ...

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...

AMD Advanced Micro Devices, Inc.